CRISPR Eye Drops Successfully Block Blood Vessel Growth in Corneal Injury Study

Corneal neovascularization, where abnormal blood vessels invade the normally clear cornea, represents a major cause of vision loss worldwide. Current treatments require invasive injections and often cause significant side effects, creating an urgent need for safer alternatives.

Researchers at Seoul National University developed the first non-viral CRISPR gene therapy delivered through simple eye drops. They used Cas9 ribonucleoproteins to target the VEGFA gene, which controls blood vessel formation, and packaged this system in liposomes for corneal penetration.

In mice with alkali-burned corneas mimicking severe chemical injuries, the treatment achieved approximately 2% gene editing efficiency at the target site. Despite this modest editing rate, the therapy dramatically reduced VEGF-A protein levels, leading to significant suppression of both blood vessel and lymphatic vessel growth. Treated corneas also showed markedly reduced inflammatory cell infiltration compared to controls.

For longevity and health optimization, this research demonstrates how precision gene editing can address age-related eye diseases that commonly cause vision loss in older adults. The topical delivery method eliminates risks associated with repeated eye injections, potentially making treatment more accessible and safer for long-term use. This approach could extend to other eye conditions involving abnormal blood vessel growth.

However, this remains early-stage research conducted only in mice. The 2% gene editing efficiency, while therapeutically effective here, may not translate directly to human applications. Long-term safety data and human clinical trials are essential before this therapy becomes available for patient use.